Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients
- 12 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 185 (1), 53-62
- https://doi.org/10.1007/s10549-020-05920-y
Abstract
Purpose Non-adherence to the oral anti-estrogen therapies (AET) tamoxifen and aromatase inhibitors in early-stage hormone receptor-positive breast cancer is associated with numerous negative clinical outcomes. Prior studies have identified that non-adherence is associated with psychological and menopause-related factors which are present during AET, but the presence of these characteristics prior to AET initiation has not been investigated. Methods Psychological and menopause symptoms (depression, generalized anxiety, insomnia, somatosensory amplification, hot flash frequency, and hot flash-related interference) were assessed pre-AET initiation as predictors of subsequent non-adherence in 73 participants (Mage = 55.0, SD = 10.1 years). Participants self-reported treatment adherence after three and 6 weeks on AET. Participants who did not initiate treatment were excluded from the analysis. Results Discriminant function analyses revealed that the hypothesized set of psychological and menopause symptoms at baseline (pre-AET) together statistically distinguished between those who were non-adherent (n = 19; 26.0%) from adherent (n = 54; 74.0%) at 6 weeks. Model classification accuracy was statistically significant (Wilks’ ƛ = 0.782, χ2(6) = 15.50, p = 0.017) at the 6-week timepoint. Results were consistent at 3 weeks. Pre-AET psychological and menopause symptoms correctly classified 6-week treatment adherence 77.9% of the time. Depression contributed most to distinguishing between adherers and non-adherers. Conclusions The presence of a composite profile of psychological and menopause symptoms prior to AET initiation may help to identify early treatment non-adherence. Results can be used to identify patients at risk for non-adherence and to guide psychological and symptom management interventions.Keywords
This publication has 52 references indexed in Scilit:
- Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysisBreast Cancer Research and Treatment, 2013
- Patient-Reported Discontinuation of Endocrine Therapy and Related Adverse Effects Among Women With Early-Stage Breast CancerJournal of Oncology Practice, 2012
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Cancer treatment adherence among low‐income women with breast or gynecologic cancerCancer, 2009
- The PHQ-8 as a measure of current depression in the general populationJournal of Affective Disorders, 2009
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of Internal Medicine, 2006
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Somatization, somatosensory amplification, attribution styles and illness behaviour: A reviewInternational Review of Psychiatry, 2006
- The Hot Flash Related Daily Interference Scale: A Tool for Assessing the Impact of Hot Flashes on Quality of Life Following Breast CancerJournal of Pain and Symptom Management, 2001